Analyst: Eli Lilly price drop is a sign of competitive US insulin market
Eli Lilly has lowered the price of its cheapest insulin products in the US, and according to an analyst, this is a clear expression of the intense competition on the market.
BY MARKETWIRE, TRANSLATED BY DANIEL PEDERSEN
The US-based pharmaceutical company Eli Lilly's price reduction on its already cheapest insulin products signifies the tough competition on the US insulin market, in which the company is fighting for its market share with, for instance, Denmark's Novo Nordisk.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
.jpg)
Eli Lilly to raise millions for green initiatives
For subscribers
.jpg&w=384&q=75)
